Network meta-analysis

Level 2 or 3 hypoglycemia (participants)

Type 2 diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)

Randomized trials

Treatments

13,632

Participants

4,140

Events

In plain language

Across 32 trials with 13,632 participants, 1 of 34 treatments had a clearly better result than placebo on level 2 or 3 hypoglycemia (participants), 12 a clearly worse one, and for 21 the evidence could not tell them apart from placebo. The most favorable estimate was for Sitagliptin: hazard ratio (from event counts) 0.10 (95% credible interval 0.01 to 0.58).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Sitagliptin SITAGLIPTIN	0.10 (0.01 to 0.58)	0.01 to 0.60	Better
Danuglipron 10 mg tablet twice daily DANU_PO_10MG_BID	0.22 (0.00 to 5.01)	0.00 to 5.05	Unclear
Exenatide extended release 2 mg subcutaneous once weekly EXENER_SC_2MG_QW	0.51 (0.01 to 34.85)	0.01 to 37.39	Unclear
Polyethylene glycol loxenatide 300 µg injection once weekly PEGLOX_SC_300UG_QW	0.57 (0.01 to 40.40)	0.01 to 41.65	Unclear
Polyethylene glycol loxenatide 400 µg injection once weekly PEGLOX_SC_400UG_QW	0.57 (0.01 to 36.43)	0.01 to 36.37	Unclear
Lixisenatide 20 ug subcutaneous once daily LIXI_SC_20UG_QD	0.59 (0.26 to 1.33)	0.25 to 1.40	Unclear
Tirzepatide 1 mg subcutaneous once weekly TIRZ_SC_1MG_QW	0.59 (0.05 to 3.30)	0.05 to 3.41	Unclear
Efpeglenatide 8 mg injection every 4 weeks EFPE_SC_8MG_Q4W	0.60 (0.01 to 42.08)	0.01 to 44.34	Unclear
Efpeglenatide 16 mg injection every 4 weeks EFPE_SC_16MG_Q4W	0.62 (0.01 to 40.38)	0.01 to 40.29	Unclear
Efpeglenatide 12 mg injection every 4 weeks EFPE_SC_12MG_Q4W	0.64 (0.01 to 43.28)	0.01 to 43.99	Unclear
Liraglutide 0.9 mg injection once daily LIRA_SC_0p9MG_QD	1.02 (0.15 to 4.84)	0.14 to 4.96	Unclear
Tirzepatide 12 mg injection once weekly TIRZ_SC_12MG_QW	1.20 (0.17 to 5.78)	0.17 to 5.90	Unclear
Danuglipron 2.5 mg tablet twice daily DANU_PO_2p5MG_BID	1.52 (0.09 to 17.52)	0.09 to 18.03	Unclear
Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW	1.84 (0.92 to 3.75)	0.83 to 4.03	Unclear
Dulaglutide 1.5 mg subcutaneous once weekly DULA_SC_1p5MG_QW	1.87 (0.99 to 3.60)	0.90 to 3.98	Unclear
HRS-7535 30 mg tablet once daily HRS7535_PO_30MG_QD	2.19 (0.87 to 5.82)	0.82 to 6.29	Unclear
Albiglutide flexible dose injection once weekly ALBI_SC_FLEX_30-50_QW	2.23 (0.95 to 5.16)	0.89 to 5.59	Unclear
HRS-7535 90 mg tablet once daily HRS7535_PO_90MG_QD	2.48 (1.04 to 6.45)	0.96 to 7.09	Worse
Tirzepatide 5 mg subcutaneous once weekly TIRZ_SC_5MG_QW	2.90 (1.16 to 7.34)	1.07 to 7.99	Worse
Bofanglutide (GZR18) 4 mg injection once weekly BOFANG_SC_4MG_QW	3.00 (0.20 to 103)	0.19 to 104	Unclear
Standard care or no added treatment STANDARD_CARE	3.02 (0.98 to 9.52)	0.92 to 10.06	Unclear
Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW	3.20 (1.31 to 8.32)	1.20 to 8.80	Worse
Danuglipron 120 mg oral twice daily DANU_PO_120MG_BID	3.22 (0.34 to 31.91)	0.34 to 32.70	Unclear
Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW	3.26 (1.39 to 8.10)	1.29 to 8.81	Worse
Danuglipron 40 mg oral twice daily DANU_PO_40MG_BID	3.31 (0.36 to 32.06)	0.34 to 33.14	Unclear
Insulin glargine INS_GLARGINE	3.48 (1.74 to 7.03)	1.60 to 7.57	Worse
IGlarLixi 2:1 pen subcutaneous once daily titrated IGLARLIXI2_SC_TIT_QD	3.49 (1.67 to 7.13)	1.54 to 7.73	Worse
Danuglipron 80 mg oral twice daily DANU_PO_80MG_BID	3.53 (0.36 to 33.46)	0.35 to 34.76	Unclear
Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD	4.49 (1.37 to 14.21)	1.28 to 14.95	Worse
Albiglutide 50 mg subcutaneous once weekly ALBI_SC_50MG_QW	5.45 (2.00 to 15.27)	1.84 to 15.95	Worse
Exenatide 10 ug subcutaneous twice daily EXEN_SC_10UG_BID	6.05 (1.89 to 18.11)	1.78 to 18.76	Worse
Insulin lispro (prandial) INS_LISPRO	8.84 (3.53 to 22.74)	3.30 to 24.41	Worse
Glimepiride GLIMEPIRIDE	14.26 (4.96 to 41.44)	4.73 to 42.70	Worse
Premixed insulin INS_PREMIX	16.07 (3.06 to 89.09)	2.98 to 90.33	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	SITAGLIPTIN	DANU_PO_10MG_BID	EXENER_SC_2MG_QW	PEGLOX_SC_300UG_QW	PEGLOX_SC_400UG_QW	LIXI_SC_20UG_QD	TIRZ_SC_1MG_QW	EFPE_SC_8MG_Q4W	EFPE_SC_16MG_Q4W	EFPE_SC_12MG_Q4W	LIRA_SC_0p9MG_QD	TIRZ_SC_12MG_QW	DANU_PO_2p5MG_BID	DULA_SC_0p75MG_QW	DULA_SC_1p5MG_QW	HRS7535_PO_30MG_QD	ALBI_SC_FLEX_30-50_QW	HRS7535_PO_90MG_QD	TIRZ_SC_5MG_QW	BOFANG_SC_4MG_QW	STANDARD_CARE	TIRZ_SC_10MG_QW	DANU_PO_120MG_BID	TIRZ_SC_15MG_QW	DANU_PO_40MG_BID	INS_GLARGINE	IGLARLIXI2_SC_TIT_QD	DANU_PO_80MG_BID	LIRA_SC_1p8MG_QD	ALBI_SC_50MG_QW	EXEN_SC_10UG_BID	INS_LISPRO	GLIMEPIRIDE	INS_PREMIX
PLACEBO	PLACEBO	10.11 1.73 to 99.14	4.45 0.20 to 310	1.95 0.03 to 176	1.76 0.02 to 179	1.75 0.03 to 157	1.69 0.75 to 3.79	1.69 0.30 to 19.27	1.66 0.02 to 161	1.62 0.02 to 157	1.57 0.02 to 162	0.98 0.21 to 6.77	0.83 0.17 to 5.89	0.66 0.06 to 10.57	0.54 0.27 to 1.09	0.54 0.28 to 1.01	0.46 0.17 to 1.15	0.45 0.19 to 1.05	0.40 0.15 to 0.96	0.34 0.14 to 0.86	0.33 0.01 to 5.00	0.33 0.10 to 1.02	0.31 0.12 to 0.76	0.31 0.03 to 2.98	0.31 0.12 to 0.72	0.30 0.03 to 2.82	0.29 0.14 to 0.58	0.29 0.14 to 0.60	0.28 0.03 to 2.79	0.22 0.07 to 0.73	0.18 0.07 to 0.50	0.17 0.06 to 0.53	0.11 0.04 to 0.28	0.07 0.02 to 0.20	0.06 0.01 to 0.33
SITAGLIPTIN	0.10 0.01 to 0.58	SITAGLIPTIN	0.43 0.01 to 38.69	0.18 0.00 to 24.47	0.17 0.00 to 24.91	0.16 0.00 to 22.84	0.17 0.02 to 0.84	0.17 0.01 to 3.25	0.15 0.00 to 22.08	0.16 0.00 to 22.10	0.15 0.00 to 21.59	0.10 0.01 to 1.18	0.08 0.01 to 1.16	0.06 0.00 to 1.76	0.05 0.01 to 0.28	0.05 0.01 to 0.28	0.04 0.00 to 0.32	0.04 0.00 to 0.24	0.04 0.00 to 0.28	0.03 0.00 to 0.24	0.03 0.00 to 0.87	0.03 0.00 to 0.23	0.03 0.00 to 0.21	0.03 0.00 to 0.54	0.03 0.00 to 0.22	0.03 0.00 to 0.54	0.03 0.00 to 0.15	0.03 0.00 to 0.15	0.03 0.00 to 0.49	0.02 0.00 to 0.16	0.02 0.00 to 0.14	0.02 0.00 to 0.11	0.01 0.00 to 0.08	0.01 0.00 to 0.05	0.01 0.00 to 0.06
DANU_PO_10MG_BID	0.22 0.00 to 5.01	2.34 0.03 to 111	DANU_PO_10MG_BID	0.40 0.00 to 121	0.36 0.00 to 116	0.37 0.00 to 100	0.38 0.01 to 9.29	0.39 0.00 to 20.85	0.33 0.00 to 96.28	0.36 0.00 to 104	0.34 0.00 to 96.80	0.22 0.00 to 8.75	0.19 0.00 to 7.16	0.15 0.00 to 6.99	0.12 0.00 to 2.93	0.12 0.00 to 2.90	0.10 0.00 to 2.56	0.10 0.00 to 2.60	0.09 0.00 to 2.33	0.08 0.00 to 1.92	0.07 0.00 to 5.08	0.08 0.00 to 2.03	0.07 0.00 to 1.80	0.07 0.00 to 1.87	0.07 0.00 to 1.70	0.07 0.00 to 1.84	0.06 0.00 to 1.52	0.06 0.00 to 1.53	0.06 0.00 to 1.74	0.05 0.00 to 1.39	0.04 0.00 to 1.09	0.04 0.00 to 1.03	0.03 0.00 to 0.64	0.02 0.00 to 0.41	0.01 0.00 to 0.48
EXENER_SC_2MG_QW	0.51 0.01 to 34.85	5.49 0.04 to 630	2.52 0.01 to 867	EXENER_SC_2MG_QW	0.88 0.00 to 384	0.88 0.00 to 470	0.87 0.01 to 61.52	0.90 0.01 to 114	0.82 0.00 to 349	0.84 0.00 to 472	0.80 0.00 to 444	0.51 0.00 to 50.26	0.45 0.00 to 45.23	0.34 0.00 to 52.05	0.28 0.00 to 20.85	0.27 0.00 to 20.35	0.23 0.00 to 18.04	0.23 0.00 to 16.82	0.21 0.00 to 15.61	0.18 0.00 to 13.95	0.15 0.00 to 29.68	0.17 0.00 to 14.03	0.16 0.00 to 11.94	0.16 0.00 to 19.15	0.16 0.00 to 12.02	0.15 0.00 to 18.85	0.15 0.00 to 11.11	0.15 0.00 to 10.99	0.14 0.00 to 18.19	0.11 0.00 to 10.10	0.10 0.00 to 7.35	0.08 0.00 to 7.06	0.06 0.00 to 4.52	0.04 0.00 to 2.93	0.03 0.00 to 3.18
PEGLOX_SC_300UG_QW	0.57 0.01 to 40.40	6.00 0.04 to 736	2.76 0.01 to 1136	1.13 0.00 to 578	PEGLOX_SC_300UG_QW	0.98 0.00 to 395	0.96 0.01 to 74.88	1.04 0.01 to 121	0.96 0.00 to 501	0.97 0.00 to 505	0.90 0.00 to 540	0.58 0.00 to 61.10	0.48 0.00 to 53.45	0.38 0.00 to 67.22	0.31 0.00 to 23.39	0.31 0.00 to 21.96	0.25 0.00 to 21.48	0.26 0.00 to 18.78	0.23 0.00 to 18.93	0.19 0.00 to 15.56	0.18 0.00 to 30.21	0.19 0.00 to 15.07	0.17 0.00 to 14.23	0.17 0.00 to 22.55	0.17 0.00 to 13.34	0.17 0.00 to 22.88	0.16 0.00 to 12.23	0.16 0.00 to 12.45	0.16 0.00 to 21.27	0.13 0.00 to 10.28	0.10 0.00 to 8.77	0.10 0.00 to 7.95	0.06 0.00 to 5.15	0.04 0.00 to 3.22	0.04 0.00 to 3.64
PEGLOX_SC_400UG_QW	0.57 0.01 to 36.43	6.08 0.04 to 744	2.71 0.01 to 1029	1.14 0.00 to 457	1.02 0.00 to 433	PEGLOX_SC_400UG_QW	0.96 0.01 to 71.77	1.02 0.01 to 116	0.89 0.00 to 456	0.92 0.00 to 463	0.89 0.00 to 512	0.55 0.00 to 59.22	0.50 0.00 to 48.26	0.38 0.00 to 57.79	0.31 0.00 to 21.76	0.31 0.00 to 22.31	0.26 0.00 to 17.36	0.26 0.00 to 18.45	0.23 0.00 to 16.07	0.19 0.00 to 14.21	0.18 0.00 to 29.35	0.19 0.00 to 13.97	0.17 0.00 to 12.88	0.18 0.00 to 19.98	0.17 0.00 to 12.75	0.17 0.00 to 19.41	0.17 0.00 to 11.78	0.17 0.00 to 11.98	0.16 0.00 to 19.76	0.13 0.00 to 9.53	0.10 0.00 to 7.73	0.10 0.00 to 7.05	0.06 0.00 to 4.78	0.04 0.00 to 2.94	0.04 0.00 to 3.34
LIXI_SC_20UG_QD	0.59 0.26 to 1.33	5.92 1.20 to 55.12	2.64 0.11 to 182	1.15 0.02 to 115	1.05 0.01 to 118	1.04 0.01 to 102	LIXI_SC_20UG_QD	0.99 0.16 to 12.24	0.94 0.01 to 98.02	0.97 0.01 to 102	0.94 0.01 to 105	0.57 0.12 to 4.15	0.50 0.09 to 3.96	0.40 0.03 to 6.73	0.32 0.19 to 0.54	0.32 0.18 to 0.53	0.27 0.08 to 0.90	0.26 0.14 to 0.50	0.24 0.07 to 0.78	0.20 0.07 to 0.62	0.19 0.01 to 3.53	0.19 0.07 to 0.58	0.18 0.06 to 0.56	0.18 0.02 to 1.96	0.18 0.06 to 0.53	0.18 0.02 to 1.87	0.17 0.11 to 0.25	0.17 0.11 to 0.25	0.17 0.02 to 1.84	0.13 0.04 to 0.41	0.11 0.03 to 0.35	0.10 0.03 to 0.30	0.07 0.02 to 0.21	0.04 0.01 to 0.11	0.04 0.01 to 0.19
TIRZ_SC_1MG_QW	0.59 0.05 to 3.30	5.89 0.31 to 98.07	2.54 0.05 to 266	1.11 0.01 to 152	0.96 0.01 to 137	0.98 0.01 to 134	1.01 0.08 to 6.41	TIRZ_SC_1MG_QW	0.89 0.01 to 124	0.90 0.01 to 141	0.87 0.01 to 137	0.57 0.03 to 7.26	0.49 0.03 to 6.13	0.37 0.01 to 10.12	0.32 0.03 to 1.93	0.32 0.03 to 1.88	0.26 0.02 to 1.98	0.26 0.02 to 1.68	0.23 0.02 to 1.68	0.20 0.02 to 1.06	0.18 0.00 to 4.92	0.19 0.01 to 1.46	0.18 0.02 to 0.94	0.17 0.01 to 3.32	0.18 0.02 to 0.95	0.17 0.01 to 3.24	0.17 0.01 to 1.03	0.17 0.01 to 1.07	0.16 0.01 to 2.91	0.13 0.01 to 1.00	0.11 0.01 to 0.61	0.10 0.01 to 0.74	0.07 0.01 to 0.35	0.04 0.00 to 0.30	0.03 0.00 to 0.37
EFPE_SC_8MG_Q4W	0.60 0.01 to 42.08	6.68 0.05 to 770	3.03 0.01 to 1045	1.22 0.00 to 617	1.04 0.00 to 547	1.12 0.00 to 559	1.06 0.01 to 77.96	1.12 0.01 to 136	EFPE_SC_8MG_Q4W	1.02 0.00 to 462	0.98 0.00 to 447	0.61 0.00 to 59.19	0.54 0.00 to 55.86	0.43 0.00 to 66.00	0.33 0.00 to 24.38	0.33 0.00 to 23.79	0.28 0.00 to 21.94	0.27 0.00 to 20.21	0.25 0.00 to 18.27	0.21 0.00 to 16.52	0.19 0.00 to 32.98	0.20 0.00 to 16.41	0.19 0.00 to 14.51	0.19 0.00 to 25.47	0.19 0.00 to 14.79	0.19 0.00 to 24.67	0.18 0.00 to 12.76	0.18 0.00 to 12.90	0.18 0.00 to 23.32	0.14 0.00 to 11.52	0.11 0.00 to 8.48	0.10 0.00 to 8.17	0.07 0.00 to 5.29	0.04 0.00 to 3.44	0.04 0.00 to 3.72
EFPE_SC_16MG_Q4W	0.62 0.01 to 40.38	6.30 0.05 to 800	2.80 0.01 to 1079	1.19 0.00 to 548	1.03 0.00 to 530	1.08 0.00 to 547	1.03 0.01 to 75.39	1.11 0.01 to 147	0.98 0.00 to 382	EFPE_SC_16MG_Q4W	0.93 0.00 to 506	0.61 0.00 to 63.16	0.53 0.00 to 52.35	0.43 0.00 to 61.52	0.33 0.00 to 23.82	0.33 0.00 to 22.68	0.28 0.00 to 19.59	0.28 0.00 to 20.38	0.25 0.00 to 17.30	0.21 0.00 to 15.01	0.19 0.00 to 32.35	0.20 0.00 to 15.55	0.19 0.00 to 13.59	0.19 0.00 to 24.40	0.19 0.00 to 13.28	0.18 0.00 to 22.74	0.18 0.00 to 12.52	0.18 0.00 to 12.78	0.17 0.00 to 20.31	0.13 0.00 to 10.81	0.11 0.00 to 8.30	0.10 0.00 to 7.92	0.07 0.00 to 4.98	0.04 0.00 to 3.20	0.04 0.00 to 3.54
EFPE_SC_12MG_Q4W	0.64 0.01 to 43.28	6.77 0.05 to 771	2.92 0.01 to 1025	1.25 0.00 to 643	1.11 0.00 to 614	1.12 0.00 to 572	1.06 0.01 to 78.24	1.15 0.01 to 138	1.02 0.00 to 465	1.07 0.00 to 452	EFPE_SC_12MG_Q4W	0.66 0.00 to 65.43	0.54 0.00 to 60.07	0.43 0.00 to 67.74	0.35 0.00 to 25.37	0.34 0.00 to 25.51	0.29 0.00 to 22.23	0.28 0.00 to 21.60	0.25 0.00 to 18.77	0.22 0.00 to 16.83	0.19 0.00 to 33.79	0.21 0.00 to 16.33	0.19 0.00 to 15.30	0.20 0.00 to 23.60	0.19 0.00 to 14.78	0.19 0.00 to 23.28	0.18 0.00 to 13.22	0.18 0.00 to 13.21	0.18 0.00 to 23.20	0.15 0.00 to 11.09	0.12 0.00 to 9.25	0.11 0.00 to 8.38	0.07 0.00 to 5.72	0.04 0.00 to 3.49	0.04 0.00 to 3.53
LIRA_SC_0p9MG_QD	1.02 0.15 to 4.84	10.41 0.85 to 153	4.51 0.11 to 383	1.94 0.02 to 217	1.73 0.02 to 229	1.82 0.02 to 218	1.75 0.24 to 8.18	1.77 0.14 to 30.38	1.65 0.02 to 217	1.64 0.02 to 210	1.52 0.02 to 219	LIRA_SC_0p9MG_QD	0.87 0.08 to 10.35	0.65 0.03 to 15.91	0.56 0.08 to 2.37	0.55 0.08 to 2.38	0.47 0.05 to 2.91	0.46 0.06 to 2.19	0.41 0.05 to 2.56	0.35 0.04 to 2.00	0.31 0.01 to 8.85	0.34 0.04 to 1.95	0.32 0.04 to 1.79	0.31 0.02 to 4.85	0.32 0.04 to 1.75	0.30 0.02 to 4.91	0.29 0.04 to 1.27	0.30 0.04 to 1.31	0.29 0.02 to 4.50	0.23 0.03 to 1.37	0.19 0.02 to 1.09	0.17 0.02 to 0.98	0.12 0.01 to 0.66	0.07 0.01 to 0.39	0.06 0.01 to 0.55
TIRZ_SC_12MG_QW	1.20 0.17 to 5.78	12.15 0.86 to 189	5.22 0.14 to 477	2.23 0.02 to 262	2.08 0.02 to 276	2.02 0.02 to 241	2.02 0.25 to 11.69	2.03 0.16 to 32.57	1.84 0.02 to 249	1.88 0.02 to 250	1.85 0.02 to 254	1.16 0.10 to 12.93	TIRZ_SC_12MG_QW	0.79 0.03 to 20.28	0.64 0.08 to 3.45	0.64 0.08 to 3.32	0.54 0.06 to 3.31	0.53 0.07 to 3.05	0.48 0.05 to 2.94	0.41 0.06 to 1.78	0.38 0.01 to 9.41	0.39 0.04 to 2.66	0.37 0.05 to 1.59	0.36 0.02 to 6.09	0.37 0.05 to 1.49	0.35 0.02 to 5.52	0.34 0.04 to 1.85	0.34 0.04 to 1.85	0.33 0.02 to 5.61	0.26 0.03 to 1.81	0.22 0.03 to 0.99	0.20 0.02 to 1.34	0.14 0.02 to 0.57	0.08 0.01 to 0.54	0.07 0.01 to 0.71
DANU_PO_2p5MG_BID	1.52 0.09 to 17.52	15.66 0.57 to 444	6.63 0.14 to 740	2.91 0.02 to 492	2.62 0.01 to 497	2.61 0.02 to 509	2.52 0.15 to 34.47	2.70 0.10 to 81.53	2.35 0.02 to 475	2.35 0.02 to 419	2.33 0.01 to 416	1.53 0.06 to 33.06	1.26 0.05 to 29.16	DANU_PO_2p5MG_BID	0.80 0.05 to 10.68	0.80 0.05 to 10.34	0.69 0.04 to 9.44	0.67 0.04 to 9.05	0.59 0.03 to 8.47	0.51 0.03 to 7.11	0.46 0.01 to 20.99	0.49 0.03 to 7.58	0.46 0.03 to 6.28	0.47 0.03 to 5.73	0.45 0.02 to 6.10	0.47 0.02 to 5.35	0.43 0.03 to 5.77	0.42 0.03 to 5.61	0.43 0.02 to 5.31	0.33 0.02 to 5.02	0.27 0.01 to 4.03	0.25 0.01 to 3.79	0.17 0.01 to 2.38	0.10 0.01 to 1.52	0.09 0.00 to 1.71
DULA_SC_0p75MG_QW	1.84 0.92 to 3.75	18.67 3.51 to 182	8.31 0.34 to 565	3.60 0.05 to 344	3.22 0.04 to 377	3.23 0.05 to 321	3.15 1.87 to 5.24	3.12 0.52 to 37.96	3.00 0.04 to 303	3.02 0.04 to 338	2.89 0.04 to 325	1.79 0.42 to 11.88	1.55 0.29 to 11.99	1.25 0.09 to 20.93	DULA_SC_0p75MG_QW	0.99 0.68 to 1.37	0.85 0.26 to 2.67	0.83 0.46 to 1.45	0.75 0.23 to 2.22	0.63 0.22 to 1.81	0.60 0.02 to 10.31	0.61 0.23 to 1.62	0.58 0.19 to 1.61	0.58 0.05 to 5.97	0.57 0.20 to 1.52	0.56 0.05 to 5.71	0.53 0.39 to 0.70	0.53 0.37 to 0.76	0.53 0.05 to 5.55	0.41 0.15 to 1.12	0.34 0.11 to 1.03	0.31 0.11 to 0.83	0.21 0.07 to 0.59	0.13 0.05 to 0.31	0.12 0.02 to 0.54
DULA_SC_1p5MG_QW	1.87 0.99 to 3.60	18.88 3.55 to 182	8.34 0.34 to 601	3.65 0.05 to 358	3.26 0.05 to 366	3.26 0.04 to 322	3.16 1.89 to 5.41	3.16 0.53 to 37.56	3.06 0.04 to 307	3.08 0.04 to 338	2.92 0.04 to 325	1.82 0.42 to 12.17	1.57 0.30 to 11.99	1.25 0.10 to 20.62	1.01 0.73 to 1.48	DULA_SC_1p5MG_QW	0.85 0.27 to 2.59	0.83 0.46 to 1.56	0.76 0.24 to 2.24	0.64 0.23 to 1.76	0.60 0.02 to 10.60	0.62 0.23 to 1.73	0.58 0.21 to 1.56	0.59 0.05 to 5.95	0.58 0.21 to 1.49	0.57 0.05 to 5.77	0.53 0.39 to 0.77	0.54 0.37 to 0.81	0.53 0.05 to 5.66	0.42 0.14 to 1.19	0.35 0.11 to 1.02	0.31 0.11 to 0.87	0.21 0.07 to 0.58	0.13 0.05 to 0.32	0.12 0.02 to 0.56
HRS7535_PO_30MG_QD	2.19 0.87 to 5.82	22.77 3.12 to 253	9.77 0.39 to 718	4.35 0.06 to 460	3.93 0.05 to 422	3.88 0.06 to 379	3.71 1.12 to 13.10	3.78 0.50 to 51.07	3.55 0.05 to 426	3.58 0.05 to 386	3.47 0.04 to 397	2.13 0.34 to 18.39	1.86 0.30 to 16.33	1.46 0.11 to 28.41	1.18 0.37 to 3.88	1.18 0.39 to 3.74	HRS7535_PO_30MG_QD	0.98 0.28 to 3.52	0.88 0.40 to 1.93	0.76 0.20 to 2.79	0.71 0.02 to 13.76	0.73 0.17 to 3.14	0.69 0.18 to 2.42	0.69 0.06 to 8.04	0.67 0.18 to 2.39	0.65 0.06 to 7.87	0.63 0.20 to 2.06	0.63 0.20 to 2.11	0.63 0.06 to 7.13	0.49 0.11 to 2.21	0.41 0.10 to 1.60	0.37 0.09 to 1.64	0.25 0.07 to 0.92	0.15 0.04 to 0.63	0.14 0.02 to 0.91
ALBI_SC_FLEX_30-50_QW	2.23 0.95 to 5.16	22.91 4.08 to 225	9.98 0.38 to 701	4.35 0.06 to 417	3.91 0.05 to 466	3.89 0.05 to 415	3.80 2.00 to 7.16	3.80 0.60 to 47.69	3.65 0.05 to 369	3.63 0.05 to 415	3.52 0.05 to 395	2.16 0.46 to 15.54	1.90 0.33 to 15.27	1.49 0.11 to 26.02	1.21 0.69 to 2.18	1.20 0.64 to 2.17	1.02 0.28 to 3.54	ALBI_SC_FLEX_30-50_QW	0.90 0.25 to 3.02	0.77 0.24 to 2.47	0.73 0.02 to 13.11	0.74 0.24 to 2.24	0.69 0.22 to 2.13	0.69 0.06 to 7.84	0.68 0.22 to 2.10	0.68 0.06 to 7.42	0.64 0.39 to 1.04	0.64 0.38 to 1.09	0.64 0.06 to 6.98	0.50 0.16 to 1.59	0.42 0.12 to 1.40	0.37 0.12 to 1.12	0.25 0.08 to 0.80	0.16 0.05 to 0.44	0.14 0.03 to 0.74
HRS7535_PO_90MG_QD	2.48 1.04 to 6.45	25.74 3.60 to 287	11.16 0.43 to 811	4.84 0.06 to 476	4.42 0.05 to 499	4.41 0.06 to 447	4.20 1.29 to 14.81	4.37 0.59 to 57.40	4.04 0.05 to 451	3.99 0.06 to 444	3.92 0.05 to 446	2.41 0.39 to 21.32	2.10 0.34 to 18.51	1.68 0.12 to 33.01	1.34 0.45 to 4.40	1.32 0.45 to 4.18	1.14 0.52 to 2.50	1.11 0.33 to 3.95	HRS7535_PO_90MG_QD	0.86 0.24 to 3.26	0.83 0.02 to 15.94	0.83 0.20 to 3.56	0.78 0.21 to 2.87	0.78 0.07 to 8.67	0.76 0.21 to 2.75	0.75 0.07 to 8.37	0.71 0.23 to 2.35	0.71 0.23 to 2.36	0.72 0.06 to 8.23	0.55 0.13 to 2.48	0.46 0.12 to 1.84	0.42 0.10 to 1.89	0.28 0.08 to 1.08	0.17 0.04 to 0.73	0.16 0.02 to 1.02
TIRZ_SC_5MG_QW	2.90 1.16 to 7.34	29.71 4.09 to 332	13.01 0.52 to 997	5.64 0.07 to 551	5.16 0.06 to 584	5.13 0.07 to 502	4.94 1.60 to 15.10	4.88 0.94 to 55.23	4.72 0.06 to 476	4.70 0.07 to 523	4.59 0.06 to 554	2.84 0.50 to 23.25	2.42 0.56 to 16.76	1.96 0.14 to 35.72	1.58 0.55 to 4.65	1.55 0.57 to 4.38	1.32 0.36 to 4.95	1.30 0.41 to 4.13	1.17 0.31 to 4.20	TIRZ_SC_5MG_QW	0.95 0.02 to 17.55	0.96 0.23 to 3.92	0.90 0.58 to 1.38	0.88 0.08 to 10.62	0.89 0.57 to 1.36	0.88 0.08 to 9.99	0.84 0.29 to 2.43	0.84 0.29 to 2.48	0.82 0.07 to 9.68	0.65 0.16 to 2.72	0.54 0.30 to 0.99	0.49 0.12 to 1.97	0.33 0.21 to 0.50	0.21 0.05 to 0.78	0.18 0.03 to 1.16
BOFANG_SC_4MG_QW	3.00 0.20 to 103	33.35 1.15 to 1967	15.10 0.20 to 3225	6.47 0.03 to 1868	5.67 0.03 to 1667	5.71 0.03 to 1781	5.30 0.28 to 191	5.56 0.20 to 377	5.15 0.03 to 1671	5.29 0.03 to 1578	5.30 0.03 to 1585	3.18 0.11 to 164	2.64 0.11 to 143	2.17 0.05 to 168	1.68 0.10 to 56.28	1.66 0.09 to 55.97	1.42 0.07 to 52.57	1.36 0.08 to 47.86	1.21 0.06 to 45.51	1.05 0.06 to 40.97	BOFANG_SC_4MG_QW	1.02 0.05 to 40.11	0.94 0.05 to 35.56	0.96 0.03 to 64.03	0.94 0.05 to 33.35	0.95 0.02 to 57.53	0.89 0.05 to 30.24	0.90 0.05 to 30.79	0.88 0.02 to 59.52	0.70 0.03 to 26.38	0.56 0.03 to 22.42	0.51 0.03 to 20.07	0.34 0.02 to 13.52	0.21 0.01 to 8.09	0.19 0.01 to 9.03
STANDARD_CARE	3.02 0.98 to 9.52	31.18 4.35 to 359	13.33 0.49 to 1051	5.97 0.07 to 609	5.13 0.07 to 635	5.32 0.07 to 574	5.16 1.72 to 15.26	5.18 0.69 to 70.48	4.95 0.06 to 545	4.97 0.06 to 574	4.66 0.06 to 543	2.94 0.51 to 25.06	2.57 0.38 to 24.04	2.06 0.13 to 39.83	1.64 0.62 to 4.36	1.62 0.58 to 4.40	1.37 0.32 to 5.85	1.35 0.45 to 4.17	1.20 0.28 to 5.10	1.04 0.26 to 4.30	0.98 0.02 to 20.74	STANDARD_CARE	0.93 0.23 to 3.83	0.92 0.07 to 11.95	0.92 0.23 to 3.72	0.92 0.07 to 11.15	0.87 0.32 to 2.38	0.88 0.31 to 2.40	0.86 0.07 to 10.70	0.68 0.29 to 1.52	0.55 0.13 to 2.42	0.51 0.16 to 1.52	0.34 0.08 to 1.41	0.21 0.07 to 0.58	0.19 0.03 to 0.96
TIRZ_SC_10MG_QW	3.20 1.31 to 8.32	33.00 4.69 to 372	14.50 0.55 to 1109	6.24 0.08 to 621	5.72 0.07 to 639	5.77 0.08 to 561	5.45 1.80 to 17.02	5.42 1.06 to 61.81	5.31 0.07 to 560	5.26 0.07 to 567	5.13 0.07 to 605	3.13 0.56 to 25.23	2.68 0.63 to 18.96	2.19 0.16 to 38.35	1.74 0.62 to 5.22	1.71 0.64 to 4.88	1.46 0.41 to 5.51	1.44 0.47 to 4.61	1.29 0.35 to 4.69	1.11 0.73 to 1.72	1.06 0.03 to 19.84	1.07 0.26 to 4.32	TIRZ_SC_10MG_QW	0.98 0.09 to 11.78	0.99 0.63 to 1.52	0.96 0.09 to 11.62	0.92 0.33 to 2.66	0.92 0.32 to 2.73	0.92 0.08 to 10.54	0.72 0.18 to 3.08	0.59 0.34 to 1.08	0.54 0.13 to 2.23	0.36 0.24 to 0.56	0.23 0.06 to 0.86	0.20 0.03 to 1.31
DANU_PO_120MG_BID	3.22 0.34 to 31.91	34.41 1.87 to 751	14.23 0.53 to 1381	6.44 0.05 to 1039	5.78 0.04 to 919	5.66 0.05 to 865	5.45 0.51 to 59.53	5.81 0.30 to 151	5.21 0.04 to 818	5.33 0.04 to 866	5.11 0.04 to 898	3.26 0.21 to 61.05	2.81 0.16 to 53.53	2.13 0.17 to 37.12	1.72 0.17 to 18.90	1.70 0.17 to 18.49	1.45 0.12 to 17.00	1.44 0.13 to 16.39	1.29 0.12 to 15.17	1.13 0.09 to 12.26	1.04 0.02 to 38.13	1.08 0.08 to 14.17	1.02 0.08 to 11.17	DANU_PO_120MG_BID	1.01 0.08 to 11.12	0.97 0.10 to 9.13	0.92 0.09 to 9.80	0.92 0.09 to 9.99	0.93 0.10 to 8.60	0.73 0.06 to 9.47	0.60 0.05 to 7.01	0.54 0.05 to 6.87	0.37 0.03 to 4.08	0.23 0.02 to 2.78	0.20 0.01 to 3.22
TIRZ_SC_15MG_QW	3.26 1.39 to 8.10	33.06 4.60 to 370	14.82 0.59 to 1118	6.37 0.08 to 616	5.85 0.07 to 653	5.77 0.08 to 557	5.52 1.88 to 16.84	5.54 1.05 to 61.02	5.30 0.07 to 565	5.26 0.08 to 574	5.13 0.07 to 580	3.16 0.57 to 25.61	2.71 0.67 to 18.28	2.22 0.16 to 40.58	1.77 0.66 to 5.13	1.73 0.67 to 4.84	1.49 0.42 to 5.49	1.46 0.48 to 4.58	1.31 0.36 to 4.67	1.12 0.73 to 1.76	1.07 0.03 to 19.97	1.09 0.27 to 4.38	1.01 0.66 to 1.58	0.99 0.09 to 11.84	TIRZ_SC_15MG_QW	0.99 0.09 to 11.30	0.93 0.34 to 2.68	0.93 0.34 to 2.75	0.93 0.08 to 10.74	0.74 0.18 to 3.05	0.60 0.34 to 1.13	0.55 0.14 to 2.25	0.37 0.25 to 0.58	0.23 0.06 to 0.86	0.20 0.03 to 1.33
DANU_PO_40MG_BID	3.31 0.36 to 32.06	35.25 1.85 to 764	14.09 0.54 to 1446	6.71 0.05 to 1019	5.75 0.04 to 990	5.85 0.05 to 939	5.55 0.53 to 62.41	5.97 0.31 to 164	5.37 0.04 to 933	5.53 0.04 to 908	5.33 0.04 to 847	3.30 0.20 to 66.09	2.87 0.18 to 53.14	2.12 0.19 to 41.96	1.77 0.18 to 20.14	1.75 0.17 to 19.35	1.53 0.13 to 16.63	1.46 0.13 to 17.31	1.33 0.12 to 15.10	1.14 0.10 to 12.65	1.05 0.02 to 40.70	1.09 0.09 to 14.86	1.04 0.09 to 11.26	1.03 0.11 to 9.69	1.01 0.09 to 10.92	DANU_PO_40MG_BID	0.94 0.09 to 10.48	0.94 0.09 to 10.58	0.93 0.10 to 9.18	0.73 0.06 to 9.75	0.61 0.05 to 7.29	0.54 0.05 to 7.12	0.37 0.03 to 4.25	0.23 0.02 to 2.90	0.21 0.01 to 3.37
INS_GLARGINE	3.48 1.74 to 7.03	35.18 6.85 to 332	15.49 0.66 to 1095	6.81 0.09 to 656	6.10 0.08 to 690	6.04 0.08 to 612	5.91 3.95 to 8.98	5.92 0.97 to 70.25	5.69 0.08 to 557	5.63 0.08 to 641	5.47 0.08 to 611	3.40 0.78 to 22.82	2.93 0.54 to 22.61	2.33 0.17 to 39.40	1.88 1.42 to 2.57	1.87 1.30 to 2.59	1.60 0.49 to 5.01	1.56 0.96 to 2.53	1.41 0.43 to 4.27	1.19 0.41 to 3.48	1.13 0.03 to 19.88	1.15 0.42 to 3.15	1.09 0.38 to 3.07	1.09 0.10 to 11.30	1.07 0.37 to 2.95	1.07 0.10 to 10.58	INS_GLARGINE	1.00 0.83 to 1.22	0.99 0.10 to 10.37	0.78 0.28 to 2.20	0.65 0.20 to 2.02	0.58 0.20 to 1.60	0.40 0.13 to 1.14	0.25 0.09 to 0.60	0.22 0.04 to 1.07
IGLARLIXI2_SC_TIT_QD	3.49 1.67 to 7.13	34.94 6.70 to 331	15.64 0.65 to 1055	6.81 0.09 to 657	6.17 0.08 to 715	6.04 0.08 to 621	5.89 3.94 to 8.93	5.89 0.93 to 70.44	5.64 0.08 to 554	5.69 0.08 to 623	5.51 0.08 to 598	3.38 0.76 to 23.30	2.91 0.54 to 22.72	2.36 0.18 to 38.04	1.87 1.32 to 2.73	1.86 1.23 to 2.71	1.59 0.47 to 5.08	1.56 0.92 to 2.62	1.41 0.42 to 4.43	1.19 0.40 to 3.51	1.12 0.03 to 20.02	1.14 0.42 to 3.18	1.09 0.37 to 3.09	1.09 0.10 to 11.17	1.07 0.36 to 2.98	1.07 0.09 to 10.61	1.00 0.82 to 1.21	IGLARLIXI2_SC_TIT_QD	0.99 0.09 to 10.48	0.78 0.27 to 2.23	0.64 0.20 to 2.02	0.58 0.20 to 1.62	0.39 0.13 to 1.16	0.25 0.09 to 0.63	0.22 0.04 to 1.07
DANU_PO_80MG_BID	3.53 0.36 to 33.46	37.17 2.04 to 811	15.74 0.58 to 1394	6.92 0.05 to 1114	6.11 0.05 to 1036	6.20 0.05 to 955	5.99 0.54 to 64.17	6.26 0.34 to 165	5.70 0.04 to 893	5.98 0.05 to 1020	5.70 0.04 to 890	3.44 0.22 to 65.47	3.02 0.18 to 57.37	2.31 0.19 to 43.49	1.90 0.18 to 19.87	1.87 0.18 to 19.20	1.59 0.14 to 17.84	1.57 0.14 to 17.38	1.40 0.12 to 15.94	1.22 0.10 to 14.01	1.13 0.02 to 41.42	1.17 0.09 to 14.74	1.09 0.09 to 12.30	1.08 0.12 to 10.27	1.07 0.09 to 11.81	1.07 0.11 to 10.07	1.01 0.10 to 10.49	1.01 0.10 to 10.65	DANU_PO_80MG_BID	0.79 0.06 to 9.77	0.65 0.05 to 7.51	0.58 0.05 to 7.50	0.40 0.03 to 4.58	0.25 0.02 to 2.96	0.22 0.01 to 3.46
LIRA_SC_1p8MG_QD	4.49 1.37 to 14.21	45.82 6.15 to 552	19.75 0.72 to 1561	8.70 0.10 to 935	7.81 0.10 to 987	7.74 0.10 to 854	7.58 2.44 to 23.39	7.67 1.00 to 103	7.26 0.09 to 830	7.58 0.09 to 854	6.88 0.09 to 826	4.33 0.73 to 36.66	3.84 0.55 to 36.14	3.01 0.20 to 57.71	2.41 0.89 to 6.81	2.38 0.84 to 6.91	2.03 0.45 to 8.75	1.98 0.63 to 6.24	1.80 0.40 to 7.80	1.55 0.37 to 6.31	1.44 0.04 to 29.34	1.47 0.66 to 3.42	1.39 0.32 to 5.69	1.37 0.11 to 17.72	1.36 0.33 to 5.50	1.37 0.10 to 17.29	1.28 0.45 to 3.61	1.28 0.45 to 3.69	1.26 0.10 to 16.24	LIRA_SC_1p8MG_QD	0.83 0.18 to 3.58	0.75 0.30 to 1.90	0.51 0.12 to 2.11	0.31 0.13 to 0.72	0.28 0.06 to 1.31
ALBI_SC_50MG_QW	5.45 2.00 to 15.27	55.32 7.34 to 660	24.19 0.91 to 1876	10.48 0.14 to 1050	9.55 0.11 to 1100	9.52 0.13 to 950	9.17 2.83 to 30.80	9.25 1.63 to 107	8.94 0.12 to 929	8.80 0.12 to 933	8.57 0.11 to 1020	5.28 0.92 to 44.87	4.50 1.01 to 31.80	3.68 0.25 to 68.62	2.90 0.97 to 9.48	2.88 0.98 to 8.92	2.47 0.62 to 9.65	2.40 0.71 to 8.50	2.18 0.54 to 8.52	1.87 1.01 to 3.36	1.78 0.04 to 35.12	1.81 0.41 to 7.65	1.69 0.92 to 2.98	1.66 0.14 to 21.10	1.67 0.88 to 2.90	1.63 0.14 to 19.79	1.55 0.50 to 4.98	1.55 0.50 to 5.11	1.54 0.13 to 18.57	1.20 0.28 to 5.56	ALBI_SC_50MG_QW	0.90 0.21 to 4.00	0.62 0.40 to 0.92	0.38 0.09 to 1.53	0.34 0.05 to 2.27
EXEN_SC_10UG_BID	6.05 1.89 to 18.11	61.35 8.82 to 716	27.08 0.97 to 2038	11.97 0.14 to 1259	10.41 0.13 to 1207	10.51 0.14 to 1109	10.16 3.35 to 31.54	10.33 1.35 to 146	9.87 0.12 to 1123	10.00 0.13 to 1125	9.48 0.12 to 1109	5.87 1.02 to 50.21	5.05 0.75 to 46.68	4.02 0.26 to 77.55	3.21 1.21 to 9.01	3.19 1.15 to 9.02	2.73 0.61 to 11.71	2.68 0.90 to 8.41	2.41 0.53 to 10.24	2.05 0.51 to 8.26	1.96 0.05 to 39.18	1.97 0.66 to 6.07	1.85 0.45 to 7.54	1.86 0.15 to 21.93	1.83 0.44 to 7.19	1.84 0.14 to 21.99	1.71 0.62 to 5.00	1.71 0.62 to 5.04	1.72 0.13 to 21.07	1.34 0.53 to 3.38	1.11 0.25 to 4.68	EXEN_SC_10UG_BID	0.67 0.16 to 2.79	0.42 0.27 to 0.63	0.38 0.10 to 1.25
INS_LISPRO	8.84 3.53 to 22.74	89.97 12.61 to 1016	39.64 1.55 to 3033	17.05 0.22 to 1686	15.62 0.19 to 1812	15.64 0.21 to 1515	14.97 4.88 to 46.94	14.79 2.85 to 173	14.40 0.19 to 1597	14.28 0.20 to 1518	14.02 0.17 to 1654	8.56 1.51 to 71.21	7.36 1.76 to 50.30	5.94 0.42 to 106	4.77 1.69 to 14.43	4.69 1.74 to 13.58	3.99 1.09 to 15.14	3.94 1.24 to 12.74	3.52 0.93 to 12.95	3.04 1.99 to 4.70	2.91 0.07 to 55.47	2.91 0.71 to 11.99	2.74 1.79 to 4.14	2.69 0.25 to 31.93	2.71 1.74 to 4.04	2.68 0.24 to 31.56	2.53 0.88 to 7.60	2.53 0.86 to 7.63	2.50 0.22 to 29.49	1.96 0.47 to 8.44	1.62 1.09 to 2.49	1.48 0.36 to 6.13	INS_LISPRO	0.62 0.16 to 2.37	0.55 0.08 to 3.46
GLIMEPIRIDE	14.26 4.96 to 41.44	146 21.61 to 1646	63.64 2.42 to 5071	27.89 0.34 to 2895	25.12 0.31 to 2870	24.69 0.34 to 2594	24.04 8.97 to 70.66	24.55 3.37 to 331	23.61 0.29 to 2563	23.63 0.31 to 2700	22.61 0.29 to 2552	14.06 2.57 to 115	12.19 1.87 to 108	9.55 0.66 to 179	7.62 3.24 to 20.23	7.59 3.11 to 19.54	6.51 1.60 to 26.73	6.34 2.25 to 19.05	5.72 1.36 to 23.01	4.86 1.28 to 19.19	4.74 0.12 to 87.96	4.71 1.72 to 13.88	4.42 1.16 to 17.50	4.42 0.36 to 53.72	4.32 1.17 to 16.64	4.29 0.34 to 49.74	4.05 1.66 to 10.95	4.06 1.60 to 11.20	4.07 0.34 to 49.47	3.18 1.39 to 7.60	2.64 0.65 to 10.80	2.37 1.58 to 3.77	1.61 0.42 to 6.31	GLIMEPIRIDE	0.90 0.22 to 3.17
INS_PREMIX	16.07 3.06 to 89.09	166 16.09 to 2477	73.53 2.08 to 6648	31.86 0.31 to 4178	28.19 0.27 to 4226	28.08 0.30 to 3309	27.03 5.27 to 152	28.59 2.71 to 504	26.69 0.27 to 3500	28.04 0.28 to 3477	25.87 0.28 to 3637	15.95 1.82 to 197	13.76 1.41 to 171	10.72 0.58 to 285	8.55 1.85 to 46.00	8.59 1.78 to 44.31	7.20 1.10 to 50.30	7.13 1.34 to 39.88	6.35 0.98 to 44.29	5.44 0.86 to 35.85	5.18 0.11 to 137	5.32 1.04 to 29.51	4.96 0.76 to 32.59	4.97 0.31 to 83.35	4.90 0.75 to 31.51	4.80 0.30 to 77.43	4.56 0.93 to 24.37	4.63 0.93 to 24.52	4.53 0.29 to 76.69	3.63 0.76 to 17.96	2.95 0.44 to 19.97	2.62 0.80 to 10.14	1.81 0.29 to 11.80	1.11 0.32 to 4.46	INS_PREMIX

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.153 (95% CrI 0.051 to 0.357), log scale
Residual deviance: 77.2 for 85 data points
DIC: 134.3 (pD 57.1)
Largest R-hat: 1.006
Smallest ESS: bulk 730, tail 1,560
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Baseline HbA1c (percent) effect modifier, prognostic factor; 32 of 32	Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 31 of 32
NCT03131687 S000010	8.13	S1
NCT00838916 S000099	8.31	S1
SURPASS-6 S000108	8.8	S2
Lixilan-O-AP S000170	8.34	S1
NCT01476475 S000191	8.05	S1
AWARD-7 S000237	8.6	S3
NCT01584232 S000246	8.05	S1
NCT04235959 S000277	7.92	S0
NCT02081118 S000719	7.9	S1
EXENDA S000796	7.57	S1
NCT01558271 S000837	8.14	S0
NCT02200991 S001003	8.29	S2
AWARD-CHN1 S001064	7.97	S0
AWARD-8 S001068	8.4	S1
NCT00359762 S001097	7.45	S1
NCT02449603 S001146	8.78	S1
NCT03985293 S001191	8.08	S1
LixiLan-O S001199	8.1	S1
SOLID-DKD S001370	7.61	S4
AWARD-CHN2 S001404	8.37	S1
LixiLan-L S001409	8.08	S2
NCT03322631 S001634	7.99	S0
ELEGANT S001780	7.34	S4
NCT02229227 S001887	7.7	S3
LIXILAN JP-O1 S002018	8.39	S1
Lixilan-L-CN S002110	8.3	S2
NCT01425580 S002231	13.83 median	S1
NCT03311724 S002256	8.38	S1
LIXILAN JP-O2 S002305	8.04	S1
NCT06256523 S002776	8.12	not reported
S002928 S002928	7.3 median	S1
S003090 S003090	8.1	S3

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Baseline HbA1c: design means range from 7.3 (PEGLOX_SC_300UG_QW vs PEGLOX_SC_400UG_QW vs PLACEBO) to 13.8 (GLIMEPIRIDE vs LIRA_SC_1p8MG_QD) percent; threshold 0.5
FlagEligibility, hba1c entry range: a design requires hba1c 45 or more while another admits only 8.5 or less
FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 35 or less
NoteOutcome assessment, time point: selected time points span 1 to 156.54 weeks
NoteOutcome assessment, analysis set: mixed: modified_itt 4, other 1, randomized 2, safety 25
NoteOutcome assessment, definition: mixed: documented asymptomatic hypoglycemia, glucose below 3.9 mmol/L 1, documented below 3.0 mmol/L regardless of symptoms (ADA level 2) 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, documented symptomatic hypoglycemia, plasma glucose 70 mg/dL or less 1, documented symptomatic, glucose 3.9 mmol/L or less with symptoms 1, documented symptomatic, plasma glucose 3.9 mmol/L or less 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, glucose below 54 mg/dL or severe hypoglycemia 1, Grade 1 or 2 hypoglycemia below 3.9 mmol/L 1, hypoglycemia AE with BG 3.9 mmol/L or lower 1, hypoglycemia below 3.0 mmol/L or requiring assistance 1, hypoglycemia glucose 3.9 mmol/L or lower; both events mild 1, level 3 severe hypoglycemia 1, not stated 5, participants whose worst on therapy event had glucose below 3.1 mmol/L 1, patients with any glucose below 70 mg/dL 1, plasma glucose 54 mg/dL or lower 1, protocol defined severe hypoglycemia 1, severe hypoglycemia needing assistance of another person 2, severe hypoglycemia needing resuscitative help, before rescue 1, severe hypoglycemia needing third party assistance 1, severe hypoglycemia requiring assistance from another person 1, severe symptomatic hypoglycemia requiring third party assistance 1, severe, assistance of another person required 1, severe, needing assistance of another person 1, severe, requiring assistance of another person 1, total hypoglycemia, plasma glucose 70 mg/dL or less 1
NoteOutcome assessment, proportion method: mixed: not stated 31, observed 1
NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 1, not stated 30, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 5, not stated 27
NoteRisk of bias, blinding: mixed: double_blind 12, open_label 17, single_blind 3
NoteRisk of bias, funding: mixed: industry 28, mixed 2, non_industry 1, not_reported 1
NoteData handling, input conversions: arms_combined 1, count_from_percent 4, printed_denominator 9

Comparability items per trial
Trial	definition	time weeks	instrument	analysis set	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT03131687	severe hypoglycemia needing assistance of another person	30	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00838916	severe hypoglycemia needing resuscitative help, before rescue	52	not stated	safety	not stated	not stated	not stated	hypothetical	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	glucose below 54 mg/dL or severe hypoglycemia	56	not stated	safety	not stated	not stated	while_on_treatment	hypothetical	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
Lixilan-O-AP	documented plasma glucose below 3.0 mmol/L regardless of symptoms	24.43	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT01476475	Documented symptomatic, plasma glucose 3.9 mmol/L or lower	24	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
AWARD-7	total hypoglycemia, plasma glucose 70 mg/dL or less	52	not stated	safety	not stated	not stated	hypothetical	hypothetical	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	severe, needing assistance of another person	26	not stated	safety	not stated	not stated	not stated	hypothetical	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT04235959	hypoglycemia glucose 3.9 mmol/L or lower; both events mild	28	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2020	Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more
NCT02081118	hypoglycemia AE with BG 3.9 mmol/L or lower	22	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
EXENDA	not stated	28	not stated	randomized	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 11 percent; metformin 1000 mg or more
NCT01558271	severe, assistance of another person required	26	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT02200991	severe hypoglycemia needing third party assistance	4.43	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
AWARD-CHN1	severe, requiring assistance of another person	26	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	severe hypoglycemia needing assistance of another person	24	not stated	modified_itt	not stated	not stated	not stated	hypothetical	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT00359762	documented asymptomatic hypoglycemia, glucose below 3.9 mmol/L	156.54	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2006	age 18 to 85; BMI 25 to below 40; HbA1c 6.5 to below 9.0 percent on maximum tolerated metformin
NCT02449603	not stated	16	not stated	safety	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 70, HbA1c 7.5 to 10.0 percent on metformin at least 1500 mg, BMI 21 to 35
NCT03985293	protocol defined severe hypoglycemia	20	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
LixiLan-O	documented symptomatic, plasma glucose 3.9 mmol/L or less	30.14	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2014	adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in
SOLID-DKD	level 3 severe hypoglycemia	18	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
AWARD-CHN2	documented symptomatic, glucose 3.9 mmol/L or less with symptoms	52	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
LixiLan-L	severe symptomatic hypoglycemia requiring third party assistance	30	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2014	adults with T2D on basal insulin 15 to 40 U/d; HbA1c 7 to 10% and glargine 20 to 50 U after run in
NCT03322631	not stated	12	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
ELEGANT	Grade 1 or 2 hypoglycemia below 3.9 mmol/L	26	not stated	randomized	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT02229227	participants whose worst on therapy event had glucose below 3.1 mmol/L	26	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
LIXILAN JP-O1	severe hypoglycemia requiring assistance from another person	52.14	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
Lixilan-L-CN	documented below 3.0 mmol/L regardless of symptoms (ADA level 2)	30	not stated	safety	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT01425580	not stated	18	not stated	other	not stated	not stated	not stated	not stated	single_blind	mixed	2012	type 2 diabetes; HbA1c 45 to 97 mmol/mol; subclinical LV dysfunction on echocardiography; BMI 40 or less
NCT03311724	plasma glucose 54 mg/dL or lower	16	not stated	modified_itt	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
LIXILAN JP-O2	documented symptomatic hypoglycemia, plasma glucose 70 mg/dL or less	26	not stated	modified_itt	not stated	observed	not stated	not stated	open_label	industry	2016	HbA1c 7.5 to 9.5 percent; FPG 10.0 mmol/L or less; up to two OADs or three with DPP4i
NCT06256523	not stated	29	not stated	safety	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more
S002928	hypoglycemia below 3.0 mmol/L or requiring assistance	24	not stated	safety	not stated	not stated	not stated	not stated	single_blind	non_industry	2022	age 18 to 65; BMI 50 or more; type 2 diabetes
S003090	patients with any glucose below 70 mg/dL	1	not stated	modified_itt	not stated	not stated	not stated	not stated	open_label	not_reported		age over 18; type 2 diabetes over 3 months; noncritical inpatients; prior insulin under 10 units/day

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	2 / 51		R0016215:Table 3
NCT03131687	A2	TIRZ_SC_1MG_QW	30	arm, events	1 / 53		R0016215:Table 3
NCT03131687	A3	TIRZ_SC_5MG_QW	30	arm, events	4 / 55		R0016215:Table 3
NCT03131687	A4	TIRZ_SC_10MG_QW	30	arm, events	5 / 52		R0016215:Table 3
NCT03131687	A5	TIRZ_SC_15MG_QW	30	arm, events	4 / 53		R0016215:Table 3
NCT03131687	A6	DULA_SC_1p5MG_QW	30	arm, events	2 / 54		R0016215:Table 3
NCT00838916	A1	ALBI_SC_FLEX_30-50_QW	52	arm, events	88 / 516		R0025374:Table 3
NCT00838916	A2	INS_GLARGINE	52	arm, events	66 / 263		R0025374:Table 3
SURPASS-6	A1	TIRZ_SC_5MG_QW	56	arm, events	86 / 243		R0009666:Table 4
SURPASS-6	A2	TIRZ_SC_10MG_QW	56	arm, events	89 / 238		R0009666:Table 4
SURPASS-6	A3	TIRZ_SC_15MG_QW	56	arm, events	88 / 236		R0009666:Table 4
SURPASS-6	A4	INS_LISPRO	56	arm, events	519 / 711		R0009666:Table 4
Lixilan-O-AP	A1	IGLARLIXI2_SC_TIT_QD	24.43	arm, events	171 / 351		R0013321:Table 3
Lixilan-O-AP	A2	INS_GLARGINE	24.43	arm, events	161 / 350		R0013321:Table 3
Lixilan-O-AP	A3	LIXI_SC_20UG_QD	24.43	arm, events	12 / 177		R0013321:Table 3
NCT01476475	A1	IGLARLIXI2_SC_TIT_QD	24	arm, events	35 / 161		R0021236:Table 2
NCT01476475	A2	INS_GLARGINE	24	arm, events	37 / 162		R0021236:Table 2
AWARD-7	A1	INS_GLARGINE	52	arm, events	145 / 194		R0017387:Supplement Table 12
AWARD-7	A2	DULA_SC_0p75MG_QW	52	arm, events	113 / 190		R0017387:Supplement Table 12
AWARD-7	A3	DULA_SC_1p5MG_QW	52	arm, events	95 / 193		R0017387:Supplement Table 12
NCT01584232	A1	DULA_SC_0p75MG_QW	26	arm, events	47 / 181		R0016159:Results
NCT01584232	A2	INS_GLARGINE	26	arm, events	86 / 180		R0016159:Results
NCT04235959	A1	PLACEBO	28	arm, events	0 / 4		R0019570:Table 2
NCT04235959	A3	TIRZ_SC_15MG_QW	28	arm, events	1 / 10		R0019570:Table 2
NCT02081118	A1	PLACEBO	22	arm, events	0 / 51		R0009733:Results
NCT02081118	A2	EFPE_SC_8MG_Q4W	22	arm, events	0 / 52	printed_denominator	R0009733:Results
NCT02081118	A3	EFPE_SC_12MG_Q4W	22	arm, events	0 / 52	printed_denominator	R0009733:Results
NCT02081118	A4	EFPE_SC_16MG_Q4W	22	arm, events	0 / 53	printed_denominator	R0009733:Results
EXENDA	A1	EXENER_SC_2MG_QW	28	arm, events	0 / 16		R0025594:Results
EXENDA	A2	PLACEBO	28	arm, events	0 / 14		R0025594:Results
NCT01558271	A1	DULA_SC_0p75MG_QW	26	arm, events	6 / 281		R0011901:Results
NCT01558271	A2	LIRA_SC_0p9MG_QD	26	arm, events	2 / 141		R0011901:Results
NCT01558271	A3	PLACEBO	26	arm, events	1 / 70		R0011901:Results
NCT02200991	A1	LIXI_SC_20UG_QD	4.43	arm, events	7 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	1 / 67		R0024589:Table 3
AWARD-CHN1	A1	DULA_SC_1p5MG_QW	26	arm, events	2 / 244		R0014229:Table 2
AWARD-CHN1	A2	DULA_SC_0p75MG_QW	26	arm, events	2 / 248		R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	15 / 245		R0014229:Table 2
AWARD-8	A1	DULA_SC_1p5MG_QW	24	arm, events	50 / 240		R0016038:Table 3
AWARD-8	A2	PLACEBO	24	arm, events	2 / 60		R0016038:Table 3
NCT00359762	A1	EXEN_SC_10UG_BID	156.54	arm, events	122 / 515		R0016082:Results
NCT00359762	A2	GLIMEPIRIDE	156.54	arm, events	237 / 514		R0016082:Results
NCT02449603	A1	EXEN_SC_10UG_BID	16	arm, events	3 / 52	count_from_percent;printed_denominator	R0023224:Abstract
NCT02449603	A2	INS_PREMIX	16	arm, events	9 / 52	count_from_percent;printed_denominator	R0023224:Abstract
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66		R0006095:Supplement eTable 1
NCT03985293	A2	DANU_PO_2p5MG_BID	20	arm, events	1 / 68		R0006095:Supplement eTable 1
NCT03985293	A3	DANU_PO_10MG_BID	20	arm, events	0 / 68		R0006095:Supplement eTable 1
NCT03985293	A4	DANU_PO_40MG_BID	20	arm, events	2 / 71		R0006095:Supplement eTable 1
NCT03985293	A5	DANU_PO_80MG_BID	20	arm, events	2 / 67		R0006095:Supplement eTable 1
NCT03985293	A6	DANU_PO_120MG_BID	20	arm, events	2 / 72		R0006095:Supplement eTable 1
LixiLan-O	A1	IGLARLIXI2_SC_TIT_QD	30.14	arm, events	120 / 469		R0013783:Supplement Table S2
LixiLan-O	A2	INS_GLARGINE	30.14	arm, events	110 / 467		R0013783:Supplement Table S2
LixiLan-O	A3	LIXI_SC_20UG_QD	30.14	arm, events	15 / 234		R0013783:Supplement Table S2
SOLID-DKD	A1	HRS7535_PO_30MG_QD	18	arm, events	15 / 93		R0004355:Table 2
SOLID-DKD	A2	HRS7535_PO_90MG_QD	18	arm, events	17 / 94		R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	7 / 94		R0004355:Table 2
AWARD-CHN2	A1	DULA_SC_1p5MG_QW	52	arm, events	32 / 258		R0023722:Supplement Table S7
AWARD-CHN2	A2	DULA_SC_0p75MG_QW	52	arm, events	25 / 257		R0023722:Supplement Table S7
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	52 / 259		R0023722:Supplement Table S7
LixiLan-L	A1	IGLARLIXI2_SC_TIT_QD	30	arm, events	146 / 367		R0014829:Table 3
LixiLan-L	A2	INS_GLARGINE	30	arm, events	155 / 369		R0014829:Table 3
NCT03322631	A2	TIRZ_SC_5MG_QW	12	arm, events	1 / 11		R0021917:Results
NCT03322631	A4	TIRZ_SC_15MG_QW	12	arm, events	3 / 16		R0021917:Results
ELEGANT	A1	LIRA_SC_1p8MG_QD	26	arm, events	15 / 26		R0025175:Table 3
ELEGANT	A2	STANDARD_CARE	26	arm, events	8 / 24		R0025175:Table 3
NCT02229227	A1	ALBI_SC_50MG_QW	26	arm, events	290 / 402		R0008089:Table 3
NCT02229227	A2	INS_LISPRO	26	arm, events	359 / 412		R0008089:Table 3
LIXILAN JP-O1	A1	IGLARLIXI2_SC_TIT_QD	52.14	arm, events	29 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC_20UG_QD	52.14	arm, events	7 / 160		R0015751:Table 3
Lixilan-L-CN	A1	IGLARLIXI2_SC_TIT_QD	30	arm, events	141 / 212		R0014540:Supplement Table S4
Lixilan-L-CN	A2	INS_GLARGINE	30	arm, events	152 / 214		R0014540:Supplement Table S4
NCT01425580	A1	LIRA_SC_1p8MG_QD	18	arm, events	6 / 33		R0025885:Results
NCT01425580	A2	GLIMEPIRIDE	18	arm, events	17 / 29		R0025885:Results
NCT03311724	A1	PLACEBO	16	arm, events	0 / 26		R0010282:Table 2
NCT03311724	A2	TIRZ_SC_12MG_QW	16	arm, events	2 / 29		R0010282:Table 2
NCT03311724	A3+A4	TIRZ_SC_15MG_QW	16	arm, events	10 / 56	arms_combined	R0010282:Table 2
LIXILAN JP-O2	A1	IGLARLIXI2_SC_TIT_QD	26	arm, events	37 / 260	count_from_percent	R0009500:Results
LIXILAN JP-O2	A2	INS_GLARGINE	26	arm, events	32 / 261	count_from_percent	R0009500:Results
NCT06256523	A1	BOFANG_SC_4MG_QW	29	arm, events	2 / 27	printed_denominator	R0002476:Table 2
NCT06256523	A2	PLACEBO	29	arm, events	0 / 9	printed_denominator	R0002476:Table 2
S002928	A1	PLACEBO	24	arm, events	0 / 41		R0007034:Table 4
S002928	A2	PEGLOX_SC_300UG_QW	24	arm, events	0 / 41		R0007034:Table 4
S002928	A3	PEGLOX_SC_400UG_QW	24	arm, events	0 / 41		R0007034:Table 4
S003090	A1	STANDARD_CARE	1	arm, events	9 / 27	printed_denominator	R0025350:Table 3
S003090	A2	DULA_SC_0p75MG_QW	1	arm, events	3 / 27	printed_denominator	R0025350:Table 3

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab